Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the divestment of its remaining shareholding in VISUfarma, a pan-European ophthalmic specialty pharmaceutical company, has closed as expected and, as per the press release of 10 July 2020, Nicox has received the funds of €5 million.

Michele Garufi, Chairman and CEO of Nicox, said, 'We're delighted with the conclusion of this transaction and the further strengthening of our balance sheet.'

Attachments

  • Original document
  • Permalink

Disclaimer

NicOx SA published this content on 31 July 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2020 07:12:17 UTC